

ANTH BE **New diagnostic and therapeutic tools** against multidrug resistant tumours.







stratagem-cost.eu

GROWING IDEAS THROUGH NETWORKS

IN SCIENCE & TECHNOLOGY

STRATAGEM is a COST action. COST (European Cooperation in Science and Technology) is an EU funding organisation for the creation of research networks. STRATAGEM will build the first multidisciplinary network - to include academic laboratories, research institutes, and small and medium enterprises (SMEs), with a wide range of high-level and non-overlapping expertise - that will aim to improve both the diagnosis and therapy of multidrug resistant (MDR) solid tumours. The scientific community currently only has limited knowledge of the biomarkers and therapeutic tools that can be used against MDR tumours; there are no predictive/diagnostic algorithms for MDR tumours ex ante and all previous therapies against MDR tumours have failed. The key challenge of STRATAGEM is to fill these gaps by producing a comprehensive, open and user-friendly platform of knowledge on MDR tumours, by identifying new diagnostic/predictive biomarkers, and producing new, safe compounds that can be used for the personalised treatment of MDR tumours.

Roberta Fruttero • chair (Italv) Javier De Las Rivas • vice-chair (Spain)

Chiara Riganti • WG and activities coordinator (Italy) Thomas Mohr • WG1 leader (Austria) Catherine Passirani • WG2 leader (France) M. Helena Vasconcelos • WG3 leader (Portugal) Simona Saponara • WG4 leader (Italv)

Milica Pesic • STSM coordinator (Serbia) José M. Padrón • scientific communicator (Spain) Jitka Viktorova • ITC conference grant coordinator (Czech Republic)

Dale Lawson • grant holder manager

Key Roles



DI TORINO

This project has received funding from the European Union as part of the Intergovernmental Programme "European Cooperation in Science and Technology (COST)"